Search Results

A PHASE II RANDOMIZED, OPEN-LABEL, TRIAL OF NAB-PACLITAXEL +GEMCITABINE WITH OR WITHOUT BOTENSILIMAB (Agen1181) IN PATIENTS WITH METASTATIC PANCREATIC CANCER WHO HAVE PROGRESSED ON PRIOR 5FU + LEUCOVORIN+ IRINOTECAN +OXALIPLATIN (FOLFIRINOX)

Welcome to another installment of our ongoing series, “Understanding Your Diagnosis.” This edition focuses on a lesser-known but equally important topic – gallbladder and bile duct cancer. As February marks Gallbladder and Bile Duct Cancer Awareness Month, it’s an ideal time to shed light on this condition, what it means for patients, the available treatment…

Cancer is a complex disease with multifactorial causes, and among these, genetics plays a significant role. Genetic mutations, both inherited and acquired during one’s lifetime, can substantially impact an individual’s susceptibility to various types of cancer. In this article, we delve into the world of genetic factors contributing to cancer development, exploring inherited and somatic…

A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

A Phase 1/3 Study to Evaluate Efficacy and Safety of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Ruxolitinib in Treatment-naïve Patients With Myelofibrosis